Research Site

Batumi 6400

4 studies enrolling now · 10 studies all time

What they study most

Advanced ER-Positive HER2-Negative Breast Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Breast Cancer, Early Breast Cancer, Chronic Kidney Disease, Endometrial Cancer, Lymphoma, Non-Hodgkin, Malignant Solid Tumour, Non-small Cell Lung Cancer, Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck, Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck

Studies at this site

• Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) — Recruiting now
• A Platform Study in Non-Small Cell Lung Cancer (NSCLC) — Recruiting now
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy — Recruiting now
• Volrustomig Priming Regimens Exploratory Phase II Platform Study — Recruiting now
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) — Recruiting now
• A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer — Running, not enrolling
• Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial) — Completed
• Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab — Completed
• Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck — Completed
• Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck — Completed